SynthesisObesity surgery2025
Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.
Synthesis in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.Nature medicine · 2026Trial
- SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.Diabetes, obesity & metabolism · 2026Observational
- GLP-1 Receptor Agonist Combination Therapy Before and After Metabolic and Bariatric Surgery: A Review of Outcomes.Journal of metabolic and bariatric surgery · 2026Review
- Primary Care Providers Perspectives of GLP-1 Receptor Agonists to Manage Recurrent Weight Gain after Metabolic Bariatric Surgery - a Qualitative Study.Obesity surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA significant number of patients encounter weight gain (WG) or inadequate weight loss (IWL) following bariatric surgery for obesity. Recent studies have explored the role of semaglutide in addressing weight management challenges in patients who have inadequate weight loss or weight gain after bariatric surgery. Despite such studies, a systematic review and meta-analysis evaluating the efficacy, safety and tolerability of semaglutide in this specific clinical context remains absent. Therefore, this study was undertaken to address this knowledge gap.
methodsDatabases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of semaglutide in the intervention arm post-bariatric surgery. Outcome was weight loss post-bariatric surgery.
resultsA total of six studies (300 participants) demonstrated significant weight reduction following semaglutide administration after bariatric surgery (WMD: - 15.730, 95% CI: - 22.140, - 9.320, p < 0.001). This effect remained robust in sensitivity analysis.
conclusionThe current data encourages the use of semaglutide for managing WG or IWL post-bariatric surgery.
Indexed as
Identifiers
40418526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.